Iodopol

Sodium Iodide (131I), the active ingredient in Iodopol, is a radioactive iodine (radiopharmaceutical) presented as a radiopharmaceutical for oral use. It is employed to target thyroid tissue for both therapeutic ablation and diagnostic imaging in patients with thyroid disorders.

GNH USA supplies Iodopol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable global distribution.

Iodopol is used in the management of thyroid‑related conditions, providing both therapeutic and diagnostic capabilities.

- Thyroid cancer: facilitates postoperative ablation of residual thyroid tissue and metastatic disease. - Hyperthyroidism: reduces hormone production by selectively destroying overactive thyroid cells. - Thyroid ablation: prepares patients for radioactive iodine therapy by eliminating functional thyroid tissue. - Diagnostic imaging of thyroid: enables scintigraphic visualization of thyroid uptake for functional assessment.

Iodopol may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting. - Metallic taste in the mouth. - Sore throat or mild neck discomfort. - Transient hypothyroidism. - Mild fatigue. - Temporary increase in thyroid pain.

Serious or Rare Side Effects: - Aplastic anemia or severe bone‑marrow suppression. - Radiation‑induced thyroiditis. - Pulmonary fibrosis. - Allergic or anaphylactic reaction. - Secondary malignancies due to radiation exposure. - Severe hypothyroidism requiring lifelong hormone replacement.

When prescribing Iodopol, clinicians should observe several safety measures to minimize risk.

- Pregnancy: avoid use unless benefits outweigh risks, as fetal thyroid may be affected. - Breastfeeding: discontinue breastfeeding before administration; iodine can be secreted in milk. - Renal impairment: adjust dose or monitor closely due to reduced clearance. - Thyroid function: assess baseline status and monitor post‑treatment. - Concomitant iodine: avoid other iodine‑containing drugs that may interfere with uptake. - Store below 25°C: keep in original container, protect from moisture and light.

Iodopol can interact with other agents that influence iodine metabolism or radiation sensitivity.

Major Interactions (Avoid): - Antithyroid drugs (e.g., propylthiouracil, methimazole): block iodine uptake. - Lithium: impairs thyroid hormone release, altering treatment effect. - Amiodarone: high iodine load may reduce efficacy.

Moderate Interactions (Monitor Closely): - Radioactive contrast agents: compete for iodine uptake. - Corticosteroids: may reduce radiation‑induced inflammation. - Chemotherapeutic agents affecting bone marrow: increase risk of hematologic toxicity.